

AbCheck Releases the AbAccel Antibody Technology for Out-Licensing

October 28th, 2014:

For immediate release

Plzen, Czech Republic; October 28th, 2014: AbCheck s.r.o., the multi-platform antibody discovery company, announced today the release of its proprietary AbAccel antibody optimization and humanization platform for in-house use by pharma and biotech companies.

AbCheck has consistently achieved a 100-fold affinity improvement with its AbAccel platform, which was jointly developed by AbCheck and its partner Distributed Bio (San Francisco, CA, USA). The AbAccel platform enables multi-factor antibody optimization in a single process, in order to increase the affinity while simultaneously addressing stability, species cross-reactivity, specificity and humanness to generate highly developable antibodies. Importantly, the platform can be used for both human and non-human lead antibodies.

“Following the impressive performance and properties of AbAccel generated antibodies and in response to repeated licensing requests, AbCheck has decided to broaden its business strategy by granting sublicenses under which the AbAccel libraries are transferred to pharma and biotech companies,” said Dr. Volker Lang, Managing Director of AbCheck. “These libraries will enable our partners to optimize virtually all antibodies, yielding improved antibodies with human frameworks.”

AbCheck will continue to provide research collaborations in human antibody discovery and lead optimization processes to deliver GMP-ready antibodies. Proprietary Phage Display libraries and Yeast Display technology combine into the unique AbSieve technology for efficient and high quality discovery. Screening processes can be performed in virtually all antibody formats, including full length IgGs or novel bi-specific antibody formats.

About AbCheck

AbCheck s.r.o. focuses on the discovery and/or optimization of human antibodies for partner companies. AbSieve, the combined phage and yeast display platforms, is used to develop antibodies in all antibody formats including full length IgGs as well as customer-specific and novel antibody formats. AbAccel, a proprietary algorithm for affinity maturation, optimization and humanization, is combined with Phage or Yeast Display and addresses affinity maturation, developability and stability optimization of antibodies in just one step. Antibodies generated by AbCheck’s AbSieve and AbAccel platforms have extremely high specificities and affinities, they are “GMP- ready” and have improved drugability. Furthermore, the use of Yeast display allows the screening in the final antibody drug format. AbCheck has entered into several partnerships and is recognized for its expertise in antibody discovery throughout the US and Europe.

About Distributed Bio

Distributed Bio Inc is the world leader in computational antibody analysis and design. The flagship AbGenesis antibody repertoire analysis platform is now used ubiquitously by the biotechnology industry, including 7 of the top 10 pharmas. Using proprietary algorithms AbGenesis can provide unprecedented levels of insight from a single plate up to several billion sequences. Our advanced repertoire of engineering programs enable the most cutting edge library applications, such as the AbAccel program. Tomorrow’s biotherapeutics are being built atop our algorithms.

For further information:

AbCheck s.r.o.

Dr. Volker Lang,

Managing Director

Phone: +420 378 051500

Fax: +420 378 051506

V.Lang@abcheck.eu